Company Overview
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Why Investors Should Care
Generates a return on equity of 50.2%, reflecting efficient use of shareholder capital.
Trades at a P/E of 7.6, below the sector median of 25.9.
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $107.46M (+66.9% YoY); net profit $105.89M.
- Trailing 12 Months Year-on-year growth — revenue +15.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.46% |
| 1 Year: | 15.00% |
Stock Price Performance
| 1 Year: | +47.60% |
| 6 Months: | -13.84% |
| 3 Months: | +1.99% |
| 1 Month: | +1.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.21 · Neutral
P/E of 7.59 is below the sector median of 25.88 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 50.2%.
- Generates positive free cash flow.
CONS
- Revenue declined at -1.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TBPH Theravance Biopharma, Inc. R2K | 16.93 | 7.59 | $877.45M | 0.00% | -0.81% | 50.17% | -1.46% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 3.09M | 3.51M | 4.28M | 4.51M | 8.32M | 23.48M | 12.84M | 15.74M | 5.34M | 26.15M | 12.43M | 29.50M | 19.86M | 15.01M | 18.26M | 18.73M | 14.26M | 12.91M | 13.19M | 14.95M | 13.20M | 11.05M | 12.45M | 14.65M | 10.42M | 13.75M | 15.69M | 17.57M | 14.50M | 14.26M | 16.87M | 18.75M | 15.39M | 26.20M | 19.99M | 45.89M | 17.70M |
| Operating Income | -47.50M | -33.49M | -57.83M | -58.83M | -65.12M | -57.00M | -79.18M | -64.98M | -48.70M | -62.45M | -62.62M | -73.67M | -42.48M | -65.20M | -70.57M | -72.48M | -72.18M | -76.61M | -76.49M | -83.89M | -64.11M | -53.62M | -56.17M | -38.50M | -26.88M | -9.14M | -17.43M | -24.91M | -16.12M | -8.76M | -6.24M | -11.21M | -15.71M | -10.84M | -9.20M | -14.43M | -2.73M | -6.46M | 20.01M | -9.48M |
| Net Income | -47.23M | -33.96M | -67.33M | -65.32M | -66.29M | -66.88M | -86.92M | -65.09M | -40.82M | -59.43M | -50.19M | -72.58M | -39.84M | -58.43M | -65.61M | -83.05M | -62.89M | -73.64M | -58.43M | -79.68M | -52.41M | -35.31M | -32.03M | -25.95M | -8.19M | 916.63M | -10.36M | -22.09M | -15.64M | -8.95M | -8.51M | -11.66M | -16.53M | -12.70M | -15.53M | -13.58M | 54.84M | 3.62M | 61.02M | -4.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.40 | -1.00 | -1.16 | -0.92 | -1.24 | -0.80 | -0.48 | -0.43 | -0.34 | -0.11 | 12.14 | -0.15 | -0.35 | -0.28 | -0.17 | -0.17 | -0.24 | -0.34 | -0.26 | -0.31 | -0.27 | 1.08 | 0.07 | 1.15 | -0.10 |
| R&D Expense | 32.07M | 31.95M | - | 40.56M | 42.93M | 39.34M | - | 47.77M | 48.62M | 52.69M | - | 53.82M | 46.40M | 52.01M | - | 66.01M | 62.40M | 67.37M | - | 67.60M | 51.09M | 43.74M | - | 23.25M | 14.92M | 9.87M | - | 14.57M | 9.43M | 8.31M | - | 8.97M | 9.95M | 9.27M | - | 11.45M | 10.49M | 8.11M | - | 5.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.15M | 226.00K | 11.69M | 42.13M | 48.65M | 15.39M | 60.37M | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M | 64.38M | 107.46M |
| Operating Income | -9.57M | -156.28M | -232.54M | -181.90M | -180.47M | -260.12M | -238.75M | -251.91M | -297.63M | -257.78M | -91.96M | -56.03M | -46.95M | -3.60M |
| Net Income | -9.57M | -156.28M | -237.04M | -182.22M | -190.67M | -285.40M | -215.52M | -236.46M | -278.02M | -199.43M | 872.13M | -55.19M | -56.42M | 105.89M |
| Diluted EPS | - | - | - | - | - | - | - | -4.25 | -4.46 | -2.87 | 11.85 | -1.00 | -1.15 | 2.06 |
| R&D Expense | 114.00M | 120.58M | 168.52M | 129.16M | 141.71M | 173.89M | 201.35M | 219.25M | 260.95M | 193.66M | 63.39M | 40.62M | 37.64M | 37.41M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 25.18M | - | 337.77M | 300.12M | 639.25M | 441.40M | 560.24M | 408.83M | 469.06M | 374.82M | 607.40M | 382.00M | 354.16M | 485.57M |
| Total Equity | -140.72M | -6.99M | -17.04M | - | 289.79M | 243.06M | 350.23M | 115.18M | -51.59M | -223.84M | -303.75M | -338.57M | 441.80M | 213.00M | 175.54M | 296.72M |
| Cash & Equivalents | - | 0 | 0 | 277.54M | 89.22M | 112.71M | 344.71M | 88.98M | 378.02M | 58.06M | 81.47M | 89.96M | 298.17M | 39.55M | 37.80M | 167.81M |
| Long Term Debt | - | - | - | - | - | - | - | 223.75M | 454.35M | 455.04M | 619.17M | 616.33M | - | 0 | - | - |
| Current Liabilities | - | - | 36.85M | - | 41.26M | 49.47M | 49.27M | 62.55M | 98.55M | 111.70M | 123.57M | 58.59M | 28.71M | 24.77M | 32.09M | 38.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -168.86M | -98.99M | -201.05M | -112.87M | -238.20M | -250.40M | -207.86M | -186.99M | -27.00M | -11.54M | 238.54M |
| Investing Cash Flow | - | - | - | 111.04M | -148.24M | -56.33M | 176.71M | -83.05M | 10.72M | 124.49M | 1.15B | -32.70M | 12.28M | -105.28M |
| Financing Cash Flow | - | - | - | 81.31M | 479.23M | 1.66M | 225.20M | 1.29M | 263.08M | 91.86M | -758.81M | -198.93M | -2.50M | -3.25M |
| Capital Expenditure | -2.59M | -2.73M | -3.11M | -2.65M | -2.13M | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | -171.50M | -101.12M | - | - | - | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 128.83M | 197.05M | 445.00K | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -7.4% | -69,152.2% | -1,989.6% | -431.8% | -371.0% | -1,690.6% | -395.5% | -343.1% | -414.2% | -466.1% | -179.1% | -97.6% | -72.9% | -3.4% |
| Net Margin % | -7.4% | -69,152.2% | -2,028.0% | -432.6% | -391.9% | -1,855.0% | -357.0% | -322.1% | -386.9% | -360.6% | 1,698.5% | -96.1% | -87.6% | 98.5% |
| ROE % | 137.0% | 917.4% | -81.8% | -75.0% | -54.4% | -247.8% | 417.8% | 105.6% | 91.5% | 58.9% | 197.4% | -25.9% | -32.1% | 35.7% |
| ROCE % | - | 1,338.5% | -78.4% | -72.6% | -30.6% | -68.7% | -51.7% | -84.8% | -86.1% | -81.5% | -15.9% | -15.7% | -14.6% | -0.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Madison Avenue Partners, LP | 18.45% | 9.51M | $161.26M |
| 2 | Weiss Asset Management Lp | 14.46% | 7.46M | $126.43M |
| 3 | Newtyn Management, Llc | 9.39% | 4.84M | $82.09M |
| 4 | Blackrock Inc. | 8.33% | 4.30M | $72.84M |
| 5 | Irenic Capital Management LP | 5.36% | 2.76M | $46.81M |
| 6 | Vanguard Capital Management LLC | 3.46% | 1.78M | $30.24M |
| 7 | State Street Corporation | 2.52% | 1.30M | $22.00M |
| 8 | Acadian Asset Management. LLC | 2.48% | 1.28M | $21.64M |
| 9 | Two Sigma Investments, LP | 2.44% | 1.26M | $21.34M |
| 10 | Geode Capital Management, LLC | 2.21% | 1.14M | $19.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TBPH
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNdTlRYjB0eER5QU5XZFBkSHBQcWtvVEhXV0ctSDUtZ1B3cEd0WFBqejV2a1NWOXhFa01UcjY1eDk2RGNPQXAwMFg1X0VyeG1LY29lMWtZVDQ4c2pSbDRuOXZBXzZLVkk0TG1CRDF4TnM3TmdqU3FGY0c2anJxMngwNXNqWUpzX210dy1uSW…
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPaFFHZGV6UWd3a3NSczl6UnAxUzhGc3dvUnZOcUxldUdCQXh2TW5iTWZHRUdQR092NTZ0YndRSlhvM1EtZXBVNzhQSHowX0V5V1pLU21RTU5LeVFrSlJxb2IzSXRpZlhjNXRrRS1CNFpiOFZjbHl0WVZ3Y3NBUlhFWmhrUkcwUXRydnpqQX…
Theravance Biopharma sale adds $17 cash and a drug royalty kicker - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUjRhN0tTVE9fcW1hMmFOdVl0MFhqRllucFY5WXFvSkE4ZFd0Smc1WUJPQkw0RlB5b1VuaXRkN1p5akVFQTVnUFUyQkxPcEtJVU5MaFFNX0h5UlNibnh1b0RxZThIbWhPaldvUUh3SFNKUlVIRm9nX2h3M3pKSnFidnBVZ3Z4RDRCdXZJQl…
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxONV9va3pDRTJ1bFc4VzZOZjBIeU83ZEo4enY5OWRaUUVNbEQ3c3RWYnVjTy1HN21zQUg1MERiZFZzRHpsUFAxaEp2Tk9wX0pJXzU1dDFoNnVBY0p0eDBaNUVfM3VzOGltR2t4ZXJsS0cyZ2hiUUxqREtpd05JYXEwMkFVSnJNb1UyQl8xZV…
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - TradingView
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOWEhZOW16c0ZDSVBHV1YwY3RSR3FVYXdqTnhuT3dLZGo4dklzZ1ZBUWJJSTNEaTBSYU9TWnliMGtQNS0wWFpGY003aXc5RTVxMkZ1bHhCbHFFYml4NE9ZRVpNZVN3WEN0Q1hQbWIzOFZNaGpsTmRkS0VtMWpPdjBtbUNyRElrWm5GcDVEX3…
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMERSdG8zMGRhejh4Z3luNmFZZEJGQnZSNTVVWUhPaVVDWl9oYUNDbHlVMGVWM1ZTRmhEWkRIMWRTbDY2b3Z5ZXVFMUxEU18weFJNTmxGWVRBcDB6Z0RhLXZiT2MtRjcweGxJOFZvZy0zWlF6QW1VbU1JTVRYMWpFMTlpdkp0Ykx0dUllOW…
TBPH — Frequently Asked Questions
What is the current share price of Theravance Biopharma, Inc. (TBPH)?
As of 2026-07-15 16:51 PDT, Theravance Biopharma, Inc. (TBPH) trades at $16.93 on NasdaqGM. Its 52-week range is $10.90 to $20.74.
What is the market capitalisation of TBPH?
Theravance Biopharma, Inc. (TBPH) has a market capitalisation of $877.45M on NasdaqGM.
What is the P/E ratio of TBPH?
TBPH trades at a trailing price-to-earnings (P/E) ratio of 7.59. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 3.01.
What is the return on equity (ROE) of TBPH?
TBPH has a return on equity (ROE) of 50.17%. Its return on capital employed (ROCE) is -0.81%.
Is TBPH a good stock to buy?
This page provides a data-driven analysis of Theravance Biopharma, Inc. (TBPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.